

# Fiscal Year 2010 Annual Review of Bladder Control Medications

Oklahoma HealthCare Authority

April 2011

## Current Prior Authorization Criteria

Tier 2 Authorization Criteria:

1. Trial of one Tier 1 medication that yielded inadequate clinical response or adverse effects, or
2. A unique indication which the Tier 1 drugs lack.

Tier 3 Authorization Criteria:

1. Trial of all Tier 2 medications that yielded inadequate clinical response or adverse effects, or
2. A unique indication which the Tier 2 drugs lack.

This category will be grandfathered.

Bladder Control Medications		
Tier 1	Tier 2	Tier 3
Flavoxate ( <b>Urispas</b> ®) Oxybutynin ( <b>Ditropan</b> ®) Tolterodine ( <b>Detrol</b> ®)	Trospium ( <b>Sanctura</b> ™) Trospium ER ( <b>Sanctura XR</b> ™)	Oxybutynin ER Tabs ( <b>Ditropan XL</b> ®) Oxybutynin Patch ( <b>Oxytrol</b> ®) Oxybutynin Gel ( <b>Gelnique</b> ™) Tolterodine ER Tabs ( <b>Detrol LA</b> ®) Fesoterodine ( <b>Toviaz</b> ™) Solifenacin ( <b>VESIcare</b> ®) Darifenacin ( <b>Enablex</b> ®)


\*hyoscyamine can be used as adjuvant therapy only. By itself, it will not count as a tier-1 trial.

## Utilization of Bladder Control Medications

### Comparison of Fiscal Years

Fiscal Year	Total Members	Total Claims	Total Cost	Cost per Claim	Per-Diem Cost	Total Units	Total Days
2009	3,051	12,323	\$1,207,813.61	\$98.01	\$2.96	785,119	408,624
2010	3,135	12,901	\$1,165,543.20	\$90.35	\$2.76	846,605	422,645
% Change	2.80%	4.70%	-3.50%	-7.80%	-6.80%	7.80%	3.40%
Change	84	578	-\$42,270.41	-\$7.66	-\$0.20	61,486	14,021

### Demographics of Members Utilizing Bladder Control Medications: FY 2010



### Top Prescribers of Bladder Control Medications by Number of Claims: FY 2010

Specialty	Claims
Family Practitioner	3,947
Urologist	2,211
Internist	1,079
General Practitioner	1,078
Physician Assistant	875
Nurse Practitioner (Other)	853
General Pediatrician	740
OHCA Non-Contracted Prescriber	696
Obstetrician/Gynecologist	280
General Surgeon	212
Psychiatrist	167

### Prior Authorization of Bladder Control Medications

There were a total of 686 petitions submitted for this PBPA category during fiscal year 2010. For this PBPA category, the system will automatically search for Tier 1 medications in member's claims history within specified timeframe and if detected, the member can automatically get the Tier 2 medication without submitting a prior authorization form. The following chart shows the status of the submitted petitions.

Status	Total PA Count
Approved	137
Denied	20
Incomplete	529

## Market News and Update

---

### Upcoming Patent expirations:

- Patent expiration for Detrol and Detrol LA is in March 2012. There are two manufacturers of tolterodine with tentative approval from FDA.
- The patent for Enablex expires in March 2015.

### FDA warnings:

- July 2010 - solifenacin, October 2010 - darifenacin, January 2011 - trospium, February 2011 – fexoterodine - Angioedema of the face, lips, tongue, and/or larynx has been reported with the above drugs. In some cases angioedema occurred after the first dose. Angioedema associated with upper airway swelling may be life-threatening. If involvement of the tongue, hypopharynx, or larynx occurs, medication should be promptly discontinued and appropriate therapy and/or measures to ensure a patent airway should be promptly provided.
- January 2011 - Angioedema requiring hospitalization and emergency medical treatment has occurred with the first or subsequent doses of oral oxybutynin. In the event of angioedema, oxybutynin containing products should be discontinued and appropriate therapy promptly provided.

## Conclusion and Recommendations

---

The College of Pharmacy recommends no changes to this PBPA category at this time.

## Utilization Details of Bladder Control Medications: Fiscal Year 2010

Medication	Claims	Members	Units	Days	Cost	Units/Day	Claims/Member	% Cost
OXYBUTYNIN TAB 5MG	4,179	1,310	281,071	126,922	\$43,431.83	2.21	3.19	3.73%
DETROL LA CAP 4MG	2,985	624	114,901	111,885	\$477,669.95	1.03	4.78	40.98%
OXYBUTYNIN SYP 5MG/5ML	987	334	244,866	26,865	\$10,082.17	9.11	2.96	0.87%
VESICARE TAB 5MG	699	164	26,864	24,998	\$117,714.97	1.07	4.26	10.10%
DETROL TAB 2MG	679	274	40,497	20,822	\$98,647.82	1.94	2.48	8.46%
OXYBUTYNIN TAB 10MG ER	623	103	25,116	20,440	\$41,161.44	1.23	6.05	3.53%
VESICARE TAB 10MG	486	124	18,285	17,920	\$81,391.35	1.02	3.92	6.98%
DETROL LA CAP 2MG	422	103	15,658	14,325	\$65,436.72	1.09	4.1	5.61%
ENABLEX TAB 15MG	357	100	13,144	12,214	\$56,808.35	1.08	3.57	4.87%
OXYBUTYNIN TAB 15MG ER	300	46	13,551	10,266	\$26,114.04	1.32	6.52	2.24%
ENABLEX TAB 7.5MG	245	82	8,725	8,111	\$37,248.17	1.08	2.99	3.20%
OXYBUTYNIN TAB 5MG ER	171	40	8,903	6,280	\$14,985.42	1.42	4.28	1.29%
TOVIAZ TAB 4MG	166	50	4,926	4,944	\$20,283.98	1	3.32	1.74%
FLAVOXATE TAB 100MG	161	79	11,114	3,108	\$8,747.61	3.58	2.04	0.75%
SANCTURA XR CAP 60MG	153	47	6,575	4,995	\$27,970.85	1.32	3.26	2.40%
DETROL TAB 1MG	145	59	7,697	4,188	\$18,309.62	1.84	2.46	1.57%
TOVIAZ TAB 8MG	93	20	2,768	2,768	\$11,715.71	1	4.65	1.01%
SANCTURA TAB 20MG	25	5	1,618	846	\$4,175.11	1.91	5	0.36%
OXYTROL DIS 3.9MG/24	20	4	176	649	\$3,116.69	0.27	5	0.27%
GELNIQUE GEL 10%	4	2	120	92	\$518.00	1.3	2	0.04%
HYOSCYAMINE TAB 0.15MG	1	1	30	7	\$13.40	4.29	1	0.00%
<b>TOTALS</b>	<b>12,901</b>	<b>3,135*</b>	<b>846,605</b>	<b>422,645</b>	<b>\$1,165,543.20</b>	<b>2</b>	<b>4.12</b>	

\*Total number of unduplicated members